Frontiers in Endocrinology (Mar 2022)

A Case Series of Ketoacidosis After Coronavirus Disease 2019 Vaccination in Patients With Type 1 Diabetes

  • Fumiyoshi Yakou,
  • Masuo Saburi,
  • Ai Hirose,
  • Hiroaki Akaoka,
  • Yusuke Hirota,
  • Takaaki Kobayashi,
  • Naoko Awane,
  • Nobuteru Asahi,
  • Toshihiro Amagawa,
  • Sachihiko Ozawa,
  • Atsushi Ohno,
  • Takaya Matsushita

DOI
https://doi.org/10.3389/fendo.2022.840580
Journal volume & issue
Vol. 13

Abstract

Read online

IntroductionWe report a case series of severe ketoacidosis after COVID-19 vaccination in a type 1 diabetes patients treated with insulin and an SGLT-2 inhibitor.Case ReportWe present two cases of type 1 diabetes mellitus. One patient was treated with insulin therapy and an SGLT-2 inhibitor, and the other patient was treated with insulin therapy alone. Both patients became ill after coronavirus disease-2019 vaccination, making it difficult to continue their diet or insulin injections. On admission, they developed severe diabetic ketoacidosis. This is the first report of ketoacidosis after coronavirus disease-2019 vaccination.ConclusionThe vaccine should be carefully administered to type 1 diabetes patients receiving intensive insulin therapy and a sodium-glucose transporter due to the high risk ketoacidosis. It is important to instruct patients to drink sufficient fluids and to continue insulin injections when they become sick.

Keywords